Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Policy Responses Against the COVID-19 Pandemic in Latin America

tiistai 27. huhtikuuta 2021 päivittänyt: Sebastián Peña, University of Chile

Policy Responses Against the COVID-19 Pandemic in Latin America: Interrupted Series Analyses of Local Governments

Latin America is one of the worst-hit areas from the COVID-19 pandemic worldwide. Policy responses to COVID-19 in Latin America have sought to reduce viral spread, increase the capacity of the health system response, mitigate negative consequences, and strengthen governance. Few studies have examined the effectiveness of COVID-19 policies in Latin America or explored subnational variation in their effectiveness.

In this observational study, the investigators will use a two-stage interrupted time series to estimate the effectiveness of nonpharmaceutical interventions in third-tier subnational units on SARS-COV2 transmission and COVID-19 mortality in Latin America. The investigators will estimate the effects in each local government, and then run a random-effects meta-analysis to obtain pooled effects for each intervention (and combinations of) and heterogeneity estimates. Finally, the investigators will explore potential explanations for the heterogeneity at the local level.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

The COVID-19 pandemic is spreading rapidly worldwide. Latin America, the region with the highest income inequality, remains as one of the worst-hit areas worldwide. Despite accounting for 8.4% of the global population, Latin America has witnessed 20.3% of the total SARS-COV-2 cases and 30.2% of the COVID-19 deaths to date. Several countries in the region are among the worst-hit worldwide. Brazil has had more than 11 million SARS-COV-2 cases and Mexico, Argentina and Colombia have exceeded the 2 million cases each. Similarly, the five most populated countries in the region (Brazil, Argentina, Mexico, Colombia and Peru) exceed 600,000 SARS-COV-2-related deaths. The pandemic reached Latin America later than other continents, and the first case of COVID-19 in the region was reported in Brazil on February 26, followed by a case in Mexico on February 28, 2020 and subsequently spreading throughout the region during March 2020.

Policy responses to COVID-19 in Latin America have sought to reduce viral spread, increase the capacity of the health system response, mitigate negative consequences, and strengthen governance. Effectiveness studies of social distancing policies in China, India, European countries, the United States and worldwide have shown that these appear to be effective to reduce viral transmission.

Despite the heavy burden of the COVID-19 in Latin American countries, there have been few studies examining the effectiveness of COVID-19 policies. Likewise, few studies have explored variation at the local level in the effectiveness of COVID-19 policies. Inequalities in policy effectiveness can arise due to within-country differences at the local level due to their geographical, sociodemographic, mobility patterns, and governance differences. In Latin America, high levels of poverty, urban density, household crowding, lack of safety nets, unemployment and precarious work cluster geographically and coexist with structural inequities in governance and built environments, thus creating barriers for effective compliance with preventive recommendations and for the implementation of well-functioning contact tracing and isolation mechanisms. Understanding the effectiveness of policies at the local level and exploring potential explanations for effect heterogeneity is essential to reduce the burden of the ongoing COVID-19 pandemic and inform the preparedness for future pandemics.

In this study, the investigators aim, first, to estimate the effectiveness of nonpharmaceutical interventions on SARS-COV2 transmission and COVID-19 mortality in Latin America; second, to examine the effect heterogeneity of transmission and mortality at the local level. Third, assuming there is evidence of moderate to substantial heterogeneity at the local level, the investigators aim to explore potential explanations for this heterogeneity. The study will use an interrupted time series method to estimate their effects in each local government, and random effects meta-analysis and meta-regression to obtain pooled effects, heterogeneity estimates and potential explanations.

Methods Design and setting: Natural experiment exploiting the variation in the temporal and spatial implementation of policy interventions, aimed to reduce the spread and mortality of COVID-19 in Latin America. The unit of analysis are local governments, i.e. third-tier administrative levels such as municipalities, districts or cantons.

Eligibility criteria: See below. To date, eligible countries are Argentina, Brazil, Chile, Colombia, Costa Rica, Guatemala, Mexico, Paraguay, and Peru. These countries represent 80.9% of the population in Latin America, and the vast majority of SARS-CoV-2 cases and COVID-19 deaths.

Interventions: Interventions include (i) policies aimed at reducing viral transmission, (ii) policies aimed at increasing the capacity of the health system's response, and (iii) policies aimed at mitigating the negative consequences of the epidemic and potential adverse effects of interventions. We will use the PoliMap taxonomy to categorise the examined policies.

Comparator: Counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred.

Data sources: COVID-19 cases and deaths data, as well as the covariates, from official government sources, such as the Ministry of Health and Ministry of Science and Technology. The intervention information will come from legal documents, official statements, and quantitative accounts from trustable sources.

Covariates: First model at the local level does not include covariates (see below). Second model (i.e. the meta-analysis), we will examine the change in heterogeneity after adjusting for several covariates at the local level. Local level covariates include projected population size in 2020, demographic density, age-structure of the population, household density and socioeconomic status. We will use data from official sources of information, primarily the latest national population census in each included country.

Statistical analysis: See the Statistical Analysis Plan for details on the modelling assumptions. The study will use an interrupted time series design, where each local government acts as its own control. The main strength of this design is its capacity to distinguish the effect of the intervention from secular change. The study will use a Poisson regression to model the count data (for both outcomes) and accounting for overdispersion and secular trends. A full discussion on potential biases and violations of assumptions can be found in the Statistical Analysis Plan.

In a second stage, the investigators will use random effects meta analysis to pool the effect estimates for each intervention or combination of interventions. This analysis informs whether any implemented intervention was effective to reduce COVID-19 cases and deaths and the degree of heterogeneity between the effects at the local level. If there is evidence of moderate to high levels of heterogeneity (defined as higher than 50%), the investigators will also use standard meta-regression techniques to assess whether local level determinants (see Covariates) can explain the observed heterogeneity. The investigators will build the models and test the analytical strategy using publicly available data on COVID-19 cases and deaths from Finland and Sweden from January 1 to March 31.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Odotettu)

10000

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Región Metropolitana
      • Santiago, Región Metropolitana, Chile, 8380453
        • Escuela de Salud Pública
        • Alatutkija:
          • Helena Morais, MEcon
        • Alatutkija:
          • Maria José Monsalves, PhD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Lapsi
  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

The study covers the population of included countries in Latin America. Preliminarily this represents nine countries, covering 80.9% of the total population in Latin America

Kuvaus

Inclusion Criteria:

  • Country will be eligible if they are (1) Spanish or Portuguese speaking countries in Latin America, (2) availability of open data at the subnational level for any of the outcomes

Exclusion Criteria:

  • None

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Social and public health measures against COVID-19
Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
  1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings
  2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds
  3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds
Muut nimet:
  • Non-pharmaceutical interventions against COVID-19
Control
The comparator is the pre-intervention period
The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Aikaikkuna
7-day moving average of daily confirmed cases of COVID-19/SARS-CoV-2
Aikaikkuna: Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Time-varying reproductive number of confirmed cases of COVID-19/SARS-CoV-2
Aikaikkuna: Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
7-day moving average of daily confirmed deaths of COVID-19/SARS-CoV-2
Aikaikkuna: Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Sebastián Peña, MD, PhD, Escuela de Salud Pública
  • Päätutkija: Cristóbal Cuadrado, MD, PhD, Escuela de Salud Pública

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Odotettu)

Keskiviikko 28. huhtikuuta 2021

Ensisijainen valmistuminen (Odotettu)

Maanantai 31. toukokuuta 2021

Opintojen valmistuminen (Odotettu)

Maanantai 31. toukokuuta 2021

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 23. maaliskuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 24. maaliskuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Torstai 25. maaliskuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 28. huhtikuuta 2021

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 27. huhtikuuta 2021

Viimeksi vahvistettu

Torstai 1. huhtikuuta 2021

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The study uses open access data available at the municipal/district/canton level. The investigators will include the data and statistical code as a Supplementary Appendix in the published papers.

IPD-jaon aikakehys

The Study Protocol and SAP will be available in the project OSF repository upon publication of the registration in ClinicalTrials.gov. The Statistical code will be published as a Supplementary Appendix with the publish paper or preprint.

IPD-jaon käyttöoikeuskriteerit

Any interested party can access the data and documents

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ANALYTIC_CODE

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa